New bioengineered probiotic shows promise for treating IBD
新型生物工程益生菌在治療發炎性腸道疾病方面展現潛力
更新於: 2026年6月20日 上午06:00
For millions living with Inflammatory Bowel Disease (IBD), such as Crohn’s and ulcerative colitis, traditional treatments have often focused on systemic immunosuppression.
對於數百萬名患有發炎性腸道疾病(ㄧㄢˊㄧㄢˋㄒㄧㄥˊㄔㄤˊㄉㄠˋㄐㄧˊㄅㄧㄥˋ，簡稱IBD)的患者來說，例如克隆氏症與潰瘍性結腸炎，傳統治療往往側重於全身性免疫抑制。
Now, a breakthrough in "living medicines" is ushering in a third generation of therapy.
如今，一項「活體藥物」的突破正開啟第三代治療技術。
Unlike standard probiotics that struggle to survive in the hostile, inflamed gut environment, scientists have engineered "designer" microbes.
與難以在充滿敵意且發炎的腸道環境中生存的標準益生菌不同，科學家已設計出「設計師」微生物。
Researchers at UBC Okanagan, for instance, have modified a strain of E. coli to use inflammatory compounds as a fuel source, allowing the bacteria to thrive precisely where they are needed most.
例如，不列顛哥倫比亞大學奧卡納干分校(UBC Okanagan)的研究人員改良了一種大腸桿菌，使其能將發炎化合物作為燃料來源，讓細菌能在最需要的地方精確生長。
Other innovations include "biosensors" that detect specific biomarkers and trigger the localized release of anti-inflammatory molecules.
其他創新技術包括能檢測特定生物標記並觸發局部釋放抗發炎分子的「生物感測器」。
These engineered microbes aim to strengthen the intestinal barrier, modulate the immune response, and restore balance to the gut microbiome.
這些工程化微生物旨在增強腸道屏障、調節免疫反應，並恢復腸道微生物群的平衡。
By acting locally rather than throughout the entire body, these therapies promise to reduce the side effects common with conventional biologics.
由於這些療法是局部作用而非影響全身，它們有望減少傳統生物製劑常見的副作用。
While these engineered probiotics are currently moving into human clinical trials, researchers continue to study their long-term safety and stability.
儘管這些工程化益生菌目前正進入人體臨床試驗，研究人員仍持續研究其長期安全性與穩定性。
This shift toward intelligent, site-specific therapy represents a bold new frontier in how we manage complex chronic conditions.
這種轉向智慧型、定點治療的趨勢，象徵著我們在應對複雜慢性疾病方面邁向了一個大膽的新領域。
